419 related articles for article (PubMed ID: 30808373)
1. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
3. Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences.
Vaishnavi K; Saxena N; Shah N; Singh R; Manjunath K; Uthayakumar M; Kanaujia SP; Kaul SC; Sekar K; Wadhwa R
PLoS One; 2012; 7(9):e44419. PubMed ID: 22973447
[TBL] [Abstract][Full Text] [Related]
4. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
5. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.
Baud MGJ; Bauer MR; Verduci L; Dingler FA; Patel KJ; Horil Roy D; Joerger AC; Fersht AR
Eur J Med Chem; 2018 May; 152():101-114. PubMed ID: 29702446
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53
Radhakrishnan N; Dhanjal JK; Sari AN; Ishida Y; Terao K; Kaul SC; Sundar D; Wadhwa R
Discov Oncol; 2021 Dec; 12(1):64. PubMed ID: 35201513
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
8. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
9. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach.
Rauf SM; Endou A; Takaba H; Miyamoto A
Protein J; 2013 Jan; 32(1):68-74. PubMed ID: 23315175
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.
Ahire V; Das D; Mishra KP; Kulkarni GR; Ackland L
J Environ Pathol Toxicol Oncol; 2016; 35(4):355-364. PubMed ID: 27992315
[TBL] [Abstract][Full Text] [Related]
11. Hot-spot mutants of p53 core domain evince characteristic local structural changes.
Wong KB; DeDecker BS; Freund SM; Proctor MR; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8438-42. PubMed ID: 10411893
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.
Bauer MR; Krämer A; Settanni G; Jones RN; Ni X; Khan Tareque R; Fersht AR; Spencer J; Joerger AC
ACS Chem Biol; 2020 Mar; 15(3):657-668. PubMed ID: 31990523
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations.
Nikolova PV; Wong KB; DeDecker B; Henckel J; Fersht AR
EMBO J; 2000 Feb; 19(3):370-8. PubMed ID: 10654936
[TBL] [Abstract][Full Text] [Related]
15. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
16. Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.
Malik V; Kumar V; Kaul SC; Wadhwa R; Sundar D
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530424
[TBL] [Abstract][Full Text] [Related]
17. Effect of Ashwagandha Withanolides on Muscle Cell Differentiation.
Wang J; Zhang H; Kaul A; Li K; Priyandoko D; Kaul SC; Wadhwa R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680087
[No Abstract] [Full Text] [Related]
18. Small molecule induced reactivation of mutant p53 in cancer cells.
Liu X; Wilcken R; Joerger AC; Chuckowree IS; Amin J; Spencer J; Fersht AR
Nucleic Acids Res; 2013 Jul; 41(12):6034-44. PubMed ID: 23630318
[TBL] [Abstract][Full Text] [Related]
19. MPK-09, a small molecule inspired from bioactive styryllactone restores the wild-type function of mutant p53.
Metri PK; Naz S; Kondaiah P; Prasad KR
ACS Chem Biol; 2013 Jul; 8(7):1429-34. PubMed ID: 23621494
[TBL] [Abstract][Full Text] [Related]
20. Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein.
Han ISM; Thayer KM
ACS Omega; 2024 May; 9(18):19837-19847. PubMed ID: 38737036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
